ПАНДЕМИИ ГРИППА И ПОДГОТОВКА ЖИВЫХ ГРИППОЗНЫХ ВАКЦИН ДЛЯ ИХ СДЕРЖИВАНИЯ

Е.М. Дорошенко, Е.П. Григорьева, И.Н. Исакова-Сивак, Л.Г. Руденко

Аннотация


Дан краткий исторический обзор эпидемиологической ситуации по гриппу в мире и приведены основные данные о биологии вируса гриппа, важные для разработки вакцины. Подробно рассмотрены случаи заболевания и гибели от различных подтипов вируса гриппа птиц [A(Н5N1), A(H5N6), A(H7N3), A(H7N7), A(H7N9)] среди людей, стимулировавшие проведение мониторинга, разработку национальных планов подготовки к возможному возникновению пандемий и активное международное сотрудничество в подготовке вакцин для профилактики гриппа. Обеспечение населения России живыми гриппозными вакцинами против потенциально опасных вирусов гриппа птиц, а также штаммов A(H1N1)pdm и A(H2N2) имеет важное стратегическое значение. В отделе вирусологии Института экспериментальной медицины создана коллекция потенциально пандемических штаммов вируса и проведено их всестороннее доклиническое и клиническое изучение. Доклинические исследования вакцин, разработанных на основе этих штаммов, на лабораторных животных продемонстрировали безвредность, иммуногенность и протективную активность. Кандидаты для пандемических и предпандемических живых гриппозных вакцин изучены в клинических испытаниях на взрослых волонтерах. Было показано, что вакцины ареактогенны и безвредны и что передача вируса от привитых волонтерам в контрольную группу отсутствовала. Эти исследования значительно расширили набор методов оценки иммуногенности ЖГВ, включая оценку секреторных антител и клеточный иммунный ответ. Учитывая стимуляцию перекрестно-реагирующих антител, живые гриппозные вакцины могут быть использованы как первичная мера борьбы с новыми пандемиями даже в случае, если пандемический штамм будет иметь антигенные отличия.

Ключевые слова


птичий грипп, живая гриппозная аттенуированная вакцина, пандемии, вакцинные штаммы.

Полный текст:

PDF

Литература


Григорьева ЕП, Дриневский ВП, Дорошенко ЕМ, Дешева ЮА, Ерофеева МК, Максакова ВЛ, Руденко ЛГ. Эффективность живой гриппозной реассортантной вакцины при циркуляции дрейфовых вариантов вируса гриппа. Эпидемиология и вакцинопрофилактика. 2009(1):45-53.

Карпова ЛС, Соминина АА, Бурцева ЕИ, Пелих МЮ, Феодоритова ЕЛ, Поповцева НМ, Столярова ТП, Киселев ОИ. Сравнение эпидемий гриппа в России, вызванных пандемическим вирусом гриппа A(H1N1)pdm09 в период с 2009 по 2013 г. Вопросы вирусологии. 2015;60(3):19-24.

Маринич ИГ, Карпова ЛС, Сысоева ТИ, Пелих МЮ, Поповцева НМ, Столярова ТП. Ситуация по гриппу в мире и России во втором полугодии 2007 – первом полугодии 2008 года. Эпидемиология и вакцинопрофилактика. 2009;44(1):8-14.

Grigoryeva YeP, Drinevsky VP, Doroshenko YeM, Desheva YuA, Erofeeva MK, Maksakova VL, Rudenko LG. Efficacy of live attenuated influenza vaccine during the period of circulation of drift variants of flu vitus. Epidemiologiya i Vaktsinoprofilaktika. 2009;44(1):45-53. (In Russ.)

Karpova LS, Sominina AA, Burtseva YeI, Pelikh MYu, Feodoritova YeL, Popovtseva NM, Stolyarova TP, Kiselev OI. Comparison of influenza epidemics in Russia caused by the pandemic virus A(H1N1)pdm09 in 2009-2013. Voprosy Virusologii. 2015;60(3):19-24. (In Russ.)

Marinich IG, Karpova LS, Sysoyeva TI, Pelikh MYu, Popovtseva NM, Stolyarova TP. Flu activity worldwide and in Russia in the second halfof 2007 through the first half of 2008. Epidemiologiya i Vaktsinoprofilaktika. 2009;44(1):8-14. (In Russ)

Bahl J, Pham TT, Hill NJ, Hussein IT, Ma EJ, Easterday BC, Halpin RA, Stockwell TB, Wentworth DE, Kayali G, Krauss S, Schultz- Cherry S, Webster RG, Webby RJ, Swartz MD, Smith GJ, Runstadler JA. Ecosystem Interactions Underlie the Spread of Avian Influenza A Viruses with Pandemic Potential. PLoS Pathogens. 2016;12(5):e1005620.

Briand S, Mounts A, Chamberland M. Challenges of global surveillance during an influenza pandemic. Public Health. 2011;125(5):247-56.

Carter DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, Isakova-Sivak I, Rudenko L, Ross TM. Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine. Vaccine. 2015;33(1):108-16.

Chan PKS. Outbreak of Avian Influenza A(H5N1) Virus Infection in Hong Kong in 1997. Clin Infect Diseases. 2002;34(Suppl. 2):S58-S64.

Choi YK, Nguyen TD, Ozaki H, Webby RJ, Puthavathana P, Buranathal C, Chaisingh A, Auewarakul P, Hanh NT, Ma SK, Hui PY, Guan Y, Peiris JS, Webster RG. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virology. 2005;79:10821-5.

de Jonge J, Isakova-Sivak I, van Dijken H, Spijkers S, Mouthaan J, de Jong R, Smolonogina T, Roholl P, Rudenko L. H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets. J Am Soc Gene Therap. 2016;24(5):991-1002.

Desheva JA, Rudenko LG, Rekstin AR, Swayne D, Cox NJ, Klimov AI, eds. Development of Candidate H7N3 Live Attenuated Cold-adapted Influenza Vaccine. International Conference on Options for the Control of Influenza VI 2007, June 17–23; Toronto, Ontario, Canada. Atlanta, London: International Medical Press; 2007.

Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA. 2004;101(5):1356-61.

Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine. 2010;28(42):6811-20.

Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine. 2010;28(31):4895-902.

Gustin KM, Maines TR, Belser JA, van Hoeven N, Lu X, Dong L, Isakova-Sivak I, Chen LM, Voeten JT, Heldens JG, van den Bosch H, Cox NJ, Tumpey TM, Klimov AI, Rudenko L, Donis RO, Katz JM. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J Infect Diseases. 2011;204(10):1491-9.

Isakova-Sivak I, Chen LM, Matsuoka Y, Voeten JT, Kiseleva I, Heldens JG, den Bosch H, Klimov A, Rudenko L, Cox NJ, Donis RO. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology. 2011;412(2):297-305.

Isakova-Sivak I, de Jonge J, Smolonogina T, Rekstin A, van Amerongen G, van Dijken H, Mouthaan J, Roholl P, Kuznetsova V, Doroshenko E, Tsvetnitsky V, Rudenko L. Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus. PloS One. 2014;9(7):e102339.

Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015;14(10):1313-29.

Isakova-Sivak I, Stukova M, Erofeeva M, Naykhin A, Donina S, Petukhova G, Kuznetsova V, Kiseleva I, Smolonogina T, Dubrovina I, Pisareva M, Nikiforova A, Power M, Flores J, Rudenko L. H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Human Vaccines Immunotherapeutics. 2015;11(4):970-82.

Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Diseases. 2009;199(5):711-6.

Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E, Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine. 2009;27(36):4953-60.

Kilbourne ED. Influenza pandemics of the 20th century. Emerging Infect Diseases. 2006;12(1):9-14.

Kulkarni PS, Agarkhedkar S, Lalwani S, Bavdekar AR, Jog S, Raut SK, Parulekar V, Agarkhedkar SS, Palkar S, Mangrule S. Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case controlstudy. Human Vaccines Iimmunotherapeutics. 2014;10(3):566-71.

Larionova N, Kiseleva I, Isakova- Sivak I, Rekstin A, Dubrovina I, Bazhenova E, Ross TM, Swayne D, Gubareva L, Tsvetnitsky V, Fedorova E, Doroshenko E, Rudenko L. Live Attenuated Influenza Vaccines against Highly Pathogenic H5N1 avian Influenza: Development and Preclinical Characterization. Vaccines Vaccination. 2013;4(8):208.

Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, Poon L, Webster RG. Influenza: emergence and control. J Virol. 2004;78(17):8951-9.

Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, Jones T, Kemble G, Dubovsky F. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PloS One. 2010;5(10):e13755.

Nabel GJ, Wei CJ, Ledgerwood JE. Vaccinate for the next H2N2 pandemic now. Nature. 2011;471:157-8.

Pappas C, Viswanathan K, Chandrasekaran A, Raman R, Katz JM, Sasisekharan R, Tumpey TM. Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PloS One. 2010;5(6):e11158.

Qi L, Pujanauski LM, Davis AS, Schwartzman LM, Chertow DS, Baxter D, Scherler K, Hartshorn KL, Slemons RD, Walters KA, Kash JC, Taubenberger JK. Contemporaryavian influenza a virus subtype h1, h6, h7, h10, and h15 hemagglutinin genes encode a Mammalian virulence factor similar to the 1918 pandemic virus h1 hemagglutinin. mBio. 2014;5(6): e02116-14.

Rekstin A, Desheva Y, Kiseleva I, Ross T, Swayne D, Rudenko L. Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models. Open Microbiol J. 2014;8:154-62.

Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O’Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine. 2011;29(9):1836-43.

Rudenko L, Isakova-Sivak I. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines. 2015;14(3):395-412.

Rudenko L, Isakova-Sivak I, Donina S. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine. 2013;31(42):4702-5.

Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M, Korenkov D, Matyushenko V, Sparrow E, Kieny MP. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebocontrolled, phase 1 trial. Lancet Infect Diseases. 2016;16(3):303-10.

Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskay Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, Neuzil K, Flores J, Tsvetnitsky V, Kiselev O. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebocontrolled, randomized double-blind phase I studyof live attenuated H7N3 influenza vaccine. PloS One. 2014;9(2):e87962.

Rudenko L, Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J. Clinical testing of pre-pandemic live attenuated A/H5N2 influenzacandidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Vaccine. 2015;33(39):5110-7.

Rudenko L, van den Bosch H, Kiseleva I, Mironov A, Naikhin A, Larionova N, Bushmenkov D. Live attenuated pandemic influenza vaccine: clinical studies on A/17/ California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine. 2011;29(Suppl 1):A40-4.

Rudenko LG, Slepushkin AN, Mono AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993;168(4):881-7.

Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature. 2006;440:435-6.

Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, Owusu- Edusei K, Bell B, Mead PS, Biggerstaff M, Brammer L, Davidson H, Jernigan D, Jhung MA, Kamimoto LA, Merlin TL, Nowell M, Redd SC, Reed C, Schuchat A, Meltzer MI. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clini Infect Diseases. 2011;52(Suppl 1):S75-S82.

Song L. It is unlikely that influenza viruses will cause a pandemic again like what happened in1918 and 1919. Frontiers Public Health. 2014;2:39.

Sorrell EM, Ramirez-Nieto GC, Gomez-Osorio IG, Perez DR. Genesis of pandemic influenza. Cytogenetic Genome Res. 2007;117:394-402.

Stittelaar KJ, Veldhuis Kroeze EJ, Rudenko L, Dhere R, Thirapakpoomanunt S, Kieny MP, Osterhaus AD. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine. 2011;29(49):9265-70.

Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR, Kemble G, Subbarao K. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine. 2009;27(28):3744-53.

Talaat KR, Karron RA, Luke CJ, Thumar B, McMahon BA, Chen GL, Lamirande EW, Jin H, Coelingh KL, Kemble G, Subbarao K. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine. 2011;29(17):3144-8.

Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. Human illness from avian influenza H7N3, British Columbia. Emerging Infect Diseases. 2004;10(12):2196-9.

Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooledanalysis. PLoS Med. 2011;8(7):e1001053.

Webster RG. Influenza: an emerging disease. Emerging Infect Diseases. 1998;4(3):436-41.

Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Reviews. 1992;56(1):152-79.

Webster RG, Peiris M, Chen H, Guan Y. H5N1 outbreaks and enzootic influenza. EmergingInfect Diseases. 2006;12(1):3-8.

Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 2014;22(4):183-91.




DOI: http://dx.doi.org/10.24855/biosfera.v8i3.260

© ФОНД НАУЧНЫХ ИССЛЕДОВАНИЙ "XXI ВЕК"